Biopharmaceutical group Sosei Heptares closed a $200 million round of funding from an offering of new shares and euro-yen denominated convertible bonds.
The bonds will come due 2025. Sosei Heptares will use the funds to pursue growth initiatives. Those initiatives include a potential acquisition, investments in its drug discovery platform, and licensing late-stage clinical assets to build its presence in the Japanese market.
Sosei has a pipeline of candidates in gastroenterology, immuno-oncology, inflammation and other rare/specialty indications.